COVID-19 vaccines: MEPs seek answers from industry representatives
MEPs debated ways to secure a quick and safe supply of COVID-19 vaccines on Tuesday, with representatives of pharmaceutical companies, research , and civil society.
During the public hearing, MEPs from the Committee on Environment, Public Health and Food Safety as well as the Committee on Industry, Research and Energy heard from key players including researchers, representatives from pharmaceutical companies and civil society organisations, and the European Medicines Agency (EMA). MEPs highlighted the challenge of ensuring that vaccines are available as soon as possible, while at the same time building public trust in vaccination.
A recording is available through the following links:
“Today, we have very little information on the content of the contracts that have been signed by the European Commission and some laboratories”, said the Chairman of the Committee on the Environment, Public Health and Food Safety Pascal Canfin (Renew Europe, FR) yesterday. “We wanted to have more information on the state of research, the commitments made by laboratories, and whether they will be able to meet them. We do not even know how many of these contracts there are! The lack of transparency surrounding these contracts was very clearly highlighted during this hearing where Parliament played a role in ensuring democratic accountability”, he added.
“A good vaccine must be efficient, safe, affordable, developed quickly and able to achieve EU market authorisation. We all know that developing a vaccine is a very complex process and that it takes time. But with the European Union and the world in the midst of a COVID-19 pandemic, time is one thing that we simply do not have”, said Industry, Research and Energy Committee Chair Cristian Bușoi (EPP, RO) yesterday. “The EU, however, has put a lot of effort and funding into accelerating the development, as well as making the vaccine available and securing sufficient supplies for its member states”, he added.
During the debate, industry representatives from Sanofi and Curevac reiterated their commitments to produce one billion doses in 2021, and the importance of keeping safety first. The EMA pointed out that no vaccine is 100% efficient and without risk, but vaccines will only be approved when the benefits outweigh the risks. Curevac and NGO Vaccines Europe advocated for the liability for hidden effects to be made public, as it is in the United States - a view opposed by some MEPs. A representative from Vaccines Europe also stressed that eight billion doses were needed to vaccinate 50% of the world population, whilst the annual global production is five billion doses. Members also questioned the rationale behind the confidentiality of the contracts signed between the European Commission and pharmaceutical companies, and warned against possible bottlenecks in the production of future vaccines. Some MEPs also questioned whether national legal frameworks are sufficient to ensure this production, and how to reconcile intellectual property with the need to make future vaccines widely available.
Latest News from
Commission disburses €17 billion under SURE to Italy, Spain and Poland27/10/2020 16:10:00
The European Commission has disbursed a total of €17 billion to Italy, Spain and Poland in the first instalment of financial support to Member States under the SURE instrument.
Boeing WTO case: the EU gets formal green light to impose duties on U.S. imports27/10/2020 15:25:00
The Dispute Settlement Body of World Trade Organization (WTO) yesterday formally authorised the EU to take countermeasures against the United States.
EU-African Union relations: joint communiqué of the AU Peace and Security Council and the EU Political and Security Committee27/10/2020 14:10:00
On 26 October 2020, the African Union (AU) Peace and Security Council (AU PSC) and the European Union (EU) Political and Security Committee (EU PSC) held their 12th Annual Joint Consultative Meeting, virtually, as part of their regular dialogue within the framework of Article 17 of the Protocol Relating to the Establishment of the Peace and Security Council of the African Union, and the AU – EU partnership. The meeting was co-chaired by H.E. Ambassador Osama Abdelkhalek, Permanent Representative of the Arab Republic of Egypt to the AU and Chairperson of the AUPSC for October 2020 and H.E. Ambassador Sofie From- Emmesberger, Permanent Chair of the EU PSC.
Coming up: budget 2021, Covid-19 measures, Gender Equality Week27/10/2020 13:25:00
This week MEPs will decide on their priorities for the 2021 budget, consider how the pandemic has affected fundamental values and hold the first European Gender Equality Week.
EU consumers should enjoy a “right to repair” and enhanced product safety27/10/2020 12:38:00
The Internal Market Committee proposed a series of measures to strengthen consumer protection and enhance product safety and sustainability.
The EU supports nutrition and social protection in Malawi with €39 million27/10/2020 11:33:00
As part of Team Europe's response to COVID-19 in Malawi, the European Union has allocated €39 million to mitigate the negative effects of the COVID-19 pandemic.
Refugee camps on the Greek islands: situation and challenges27/10/2020 10:38:00
The situation on the Greek islands following the destruction of the Moria refugee camp will be the focus of a debate in the Civil Liberties Committee this afternoon.
A greener, fairer, and more robust EU farm policy27/10/2020 09:25:00
The EU’s future farm policy should be more flexible, sustainable, and crisis-resilient, so that farmers can continue to deliver food security across the EU.
European climate law: Council reaches agreement on large parts of the proposal26/10/2020 15:25:00
The Council recently (23 October 2020) reached agreement on a partial general approach on the proposed European climate law.